

## LITHUANIA

### Recent and planned developments in pharmaceutical policies 2017/2018

#### Special topic: patient involvement in pricing and reimbursement of medicines

#### CHANGES IN PRICING

Since January 1, 2018 VAT for reimbursement and non-reimbursement medicines changed from 21 % to 5 %

Since July 1, 2018 modified price for generic and biosimilar medicines:

First generic enters market:

- first generic should reduce the price by 30 %;

First biosimilar enters market:

- first biosimilar should reduce the price by 20 %

#### CHANGES IN REIMBURSEMENT

Since July 1, 2018 fixed patient co-payment if medicinal product is reimbursement at 100 % level:

- If medicinal products retail price till 20 EUR – patient co-payment 20 % reimbursed (basic) price;
- medicinal products retail price more than 20 EUR – patient co-payment 4,10 Eur.

#### OTHERS CHANGES

Since July 1, 2018 change of reference countries in external price referencing:

- Reference countries are all ES countries that prices are available in database (until reference countries are 8 countries: Latvia, Estonia, Poland, Czech Republic, Hungary, Slovakia, Romania, Bulgaria);
- The reimbursement price is calculated according average of the 3 lowest prices in EU countries

Since July 1, 2018 Wholesales and pharmacy mark-up changes:

Wholesalers mark-up scheme, since July 1, 2018

Manufacturer price in EUR / Maximum wholesalers mark up of manufacturers price in EUR

up to 49,99 EUR / 0,51 EUR

from 50 EUR to 263,29 EUR / 2,45 EUR

from 263 EUR and more / 5,79 EUR

Pharmacy mark-up scheme, since July 1, 2018

Pharmacy purchasing price in EUR / Maximum pharmacy mark up of pharmacy purchasing price in EUR

up to 47,46 EUR / 1,00 EUR

from 47,46 EUR to 144,8 EUR / 5,10 EUR

from 144,81 EUR and more / 14,48 EUR

#### SPECIAL TOPIC: Patient Involvement in Pricing and Reimbursement of Medicines

##### Patient organizations involved in the Public Consultations:

Subjects of Public consultations - any legislative measure, affecting pricing, reimbursement of medicinal products, other important features of the pharmaceutical market

##### Public consultations with patient organizations are carried out by:

- \* Publishing each draft measure on the internet;
- \* Organizing meetings;
- \* Sending out the questionnaires;
- \* Giving other opportunities to comment on the draft

##### Role of Patients' Organizations:

According to the Order of the Minister of Health No 159 on the inclusion of medicinal products into the reimbursement system the representatives of the Patient organizations shall be involved in the decision-making process.

##### Patients' Organizations representatives are included:

- In the Reimbursement Committee, which are responsible for the assessment and inclusion of medicinal products into the reimbursement system;
- In the composition of the Compulsory Health Insurance Board, which are responsible for approving of planned expenditure for reimbursement medical products